Vaccine Development Atcc Together, we can work toward preventing and containing the world’s most devastating epidemics. browse our resources below to discover how atcc can support your vaccine research. Atcc and usp have launched the first set of products from their collaboration to advance quality and reduce risk in the development of biological therapeutics and vaccines.
Vaccine Development Atcc Atcc receives grant from nih to build new biomanufacturing facility at its manassas, virginia headquarters. The atcc and u.s. pharmacopeia (usp), two premier materials management and standards organizations, announced the launch of their first set of joint products to advance the quality control and reduce the risk in the manufacturing of biological therapies and vaccines. In addition to this first set of products, atcc and usp will be releasing future product portfolios that provide materials and standards for the development of biological therapies. Atcc’s biomanufacturing suite will expand the biomedical research space needed for vaccine and therapeutic developments.
Vaccine Development Atcc In addition to this first set of products, atcc and usp will be releasing future product portfolios that provide materials and standards for the development of biological therapies. Atcc’s biomanufacturing suite will expand the biomedical research space needed for vaccine and therapeutic developments. Cell lines are an integral component of vaccine research, development and production. it is therefore not surprising that aspects in the history of vaccinology can be traced through the history of derivation and investigation of cell lines. Discover how stronger infrastructure, standards, and trusted data are shaping the future of vaccine discovery, development, and global readiness. An ideal vaccine for use in a pandemic is one that is safe and effective following a single dose, and therefore, we focused on developing a sars cov 2 vaccine using the vesicular stomatitis virus (vsv) chimeric virus approach used for the ebolavirus zaire vaccine (vsv∆g zebov gp marketed as ervebo®), which was shown to be effective against. Atcc provides the virus producing cell lines, microbial strains, and pneumococcal polysaccharides needed for vaccine research and development. we have the facilities and the expertise to expand cell lines to create master and working cell banks for your assay needs.
Comments are closed.